CAS: 27003-73-2; 4-((2S,3R,4R)-4-(4-Hydroxy-3-Methoxybenzyl)-3-(Hydroxymethyl)Tetrahydrofuran-2-yl)-2-Methoxyphenol
该化合物是主要在各种植物中发现的离子体化合物,特别是某些水果的种子和锥形树木中的树苗,其特征是其个性性性,作为单一的抗氧化物存在,具有特定的光学旋转作用.该复合物具有抗氧化性特性,有助于其潜在的健康利益,包括防炎和抗癌效应. (+)-Lariciresinol也因其在植物防御机制中的作用而著称,并可能对传统医学产生影响.其分子结构由二苯并聚氨酯框架组成,这是许多乳腺的典型特征.在溶性方面,它一般在有机溶剂中溶解,但水溶解程度有限.该化合物对药理研究和食品工业具有兴趣,因为其生物活性特性.
- 英文名称4-((2S,3R,4R)-4-(4-Hydroxy-3-Methoxybenzyl)-3-(Hydroxymethyl)Tetrahydrofuran-2-yl)-2-Methoxyphenol
- 中文名称落叶松树脂醇
- IUPAC名称4-((2S,3R,4R)-4-(4-hydroxy-3-methoxybenzyl)-3-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methoxyphenol
- 其它别名(+)-LARICIRESINOL; LARICIRESINOL; (2S)-2α-(3-Methoxy-4-hydroxyphenyl)-4β-(3-methoxy-4-hydroxybenzyl)tetrahydrofuran-3β-methanol; (2S)-Tetrahydro-2α-(4-hydroxy-3-methoxyphenyl)-4β-[(4-hydroxy-3-methoxyphenyl)methyl]-3β-furanmethanol; 2-Methoxy-4-[[(2S)-tetrahydro-2α-(3-methoxy-4-hydroxyphenyl)-3β-(hydroxymethyl)furan-4β-yl]methyl]phenol; 2α-(4-Hydroxy-3-methoxyphenyl)-3β-(hydroxymethyl)-4β-(4-hydroxy-3-methoxybenzyl)tetrahydrofuran; Laricericinol
- CAS编号27003-73-2
- MFCD编号:MFCD07784476
- EINECS号:694-741-2
- FDA UNII编号:73XCE5OZB0
- 分子式:C20H24O6分子量:360.41
- 产品CID: 1249666
- 产品分类天然产物 → 木脂素
物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
(+)-lariciresinol 4'-O-β-D-glucopyranoside clemastanin B 7S,8R,8'R-(-)-Lariciresinol-4,4'-bis-O-β-D-glucopyranoside 3-methoxy-4-(phenylmethoxy)benzaldehyde 3-methoxy-4-hydroxybenzoic acid vanillin 7-acetoxy-1-(4-acetoxy-3-methoxy-phenyl)-2,3-bis-acetoxymethyl-6-methoxy-1,2,3,4-tetrahydro-naphthalene (4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl)methanol合成工艺路线路线简述
- 458-35-5 = 27003-73-2 + 83327-19-9 + 29388-59-8 + 487-36-5 + 81446-29-9
反应条件:1.1 Reagents: Nadph,Hydrogen Peroxide Solvents: Water; 1 H,Ph 7,30 °C
标题:Enantioselective Lignan Synthesis By Cell-Free Extracts Of Forsythia Koreana
作者:Umezawa,Toshiaki; Et Al
参考文献:Bioscience 日期:1994 卷标:58(2) 页码:230-4
📜(2S,3R,5R,6S)-2-[4-[[(3R,4R,5S)-4-(Hydroxymethyl)-5-[3-Methoxy-4-[(2S,3R,5R,6S)-3,4,5-Trihydroxy-6-Methyloxan-2-Yl]Oxyphenyl]Oxolan-3-Yl]Methyl]-2-Methoxyphenoxy]-6-Methyloxane-3,4,5-Triol 反应生成落叶松树脂醇
参考文献:Abe,Fumiko;Yamauchi,Tatsuo,Phytochemistry,28,(1989) N,C. 1737-1741
标题:Abe,Fumiko;Yamauchi,Tatsuo,Phytochemistry,28,(1989) N,C. 1737-1741
海关参考信息
- 2902600000-乙苯
2905121000-正丙醇
2905399001-1,3-丙二醇
2905399002-1,4-丁二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2014357576-A1
优先权日:2013-05-31
标题:Methods for enhancement of muscle protein synthesis
发明人：BREUILLE DENIS; STELLINGWERFF TRENT; MOORE DANIEL RYAN; OFFORD CAVIN ELIZABETH ANN; PHILLIPS STUART MARTIN
权利人:NESTEC SA
摘要:The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis by enhancing myofibrillar muscle protein synthesis. The method includes administering to the individual a mixed macronutrient composition having (i) an amount of whey protein that is not capable of enhancing myofibrillar protein synthesis when ingested by itself and (ii) free leucine. The composition comprises at least about 5.0 g total leucine per dose.
专利号:WO-2015040533-A1
优先权日:2013-09-19
标题:Methods for enhancing muscle protein synthesis during energy deficit
发明人：BAILEY DAVID MARK; ZALTAS ERIC SCOTT; STELLINGWERFF TRENT; MOORE DANIEL RYAN; HAWLEY JOHN ALAN; BURKE LOUISE MARY
权利人:PREMIER NUTRITION CORP
摘要:The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis during periods of negative energy balance, or energy deficit. The methods include administering to an individual suffering from energy deficit a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof. The methods also include administering to an individual suffering from energy deficit a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than doses typically recommended for individuals experiencing energy balance.
专利号:US-2014294788-A1
优先权日:2013-03-26
标 题 :Methods for enhancing muscle protein synthesis following concurrent training
发明人：BAILEY DAVID MARK; ZALTAS ERIC SCOTT; MOORE DANIEL RYAN; STELLINGWERFF TRENT
权利人:NESTEC SA
摘要:The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training. Programs for enhancing muscle adaptation resulting from concurrent training are also provided. The programs include providing a composition comprising from about 15 to about 35 g protein; and providing guidelines for consumption including a recommendation of the amount of the composition to consume immediately following concurrent training.
专利号:US-2018105546-A1
优先权日:2011-06-14
标题:Methods for Chemical Synthesis of Biologically Active Compounds Using Supramolecular Protective Groups and Novel Compounds Obtainable Thereby
专利号:CN-106148355-A
优先权日:2016-06-30
标 题:Application of the IiAP2/ERF049 gene in Isatis indigo in regulating the synthesis of lignans
专利号:US-2014243280-A1
优先权日:2011-06-14
标题:Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable Thereby
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Xiao Y, Ji Q, Gao S, Tan H, Chen R, Li Q, Chen J, Yang Y, Zhang L, Wang Z, Chen W, Hu Z. Combined transcriptome and metabolite profiling reveals that IiPLR1 plays an important role in lariciresinol accumulation in Isatis indigotica. J Exp Bot. 2015 Oct;66(20):6259-71. doi: 10.1093/jxb/erv333. Epub 2015 Jul 10. doi: 10.1021/jf404292w. Epub 2013 Dec 4. doi: 10.1016/j.jep.2015.08.037. Epub 2015 Aug 28. doi: 10.1016/j.bbrc.2011.06.004. Epub 2011 Jun 7. doi: 10.1016/j.jplph.2014.06.005. Epub 2014 Jun 23. doi: 10.1016/j.cbi.2016.07.011. Epub 2016 Jul 12. eCollection 2016.
8: Milder IE, Arts IC, van de Putte B, Venema DP, Hollman PC. Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr. 2005 Mar;93(3):393-402. doi: 10.1007/s00425-011-1492-y. Epub 2011 Aug 12. doi: 10.1016/j.plaphy.2013.06.001. Epub 2013 Jun 15. doi: 10.1021/jf203222w. Epub 2011 Nov 22. doi: 10.1002/ijc.23614. doi: 10.1007/s00709-013-0505-z. Epub 2013 May 8. doi: 10.1055/s-0030-1250036. Epub 2010 May 31. Epub 2007 Jan 18. doi: 10.1016/j.numecd.2009.02.003. Epub 2009 Apr 10.
合成参考文献
摘要:Mondal, M.; Bora, U., Science of Synthesis: Metal-Catalyzed Cyclization Reactions, (2016) 2, 514.
参考文献:10.1186/1471-2164-15-388
摘要:Li Q, Chen J, Xiao Y, Di P, Zhang L, Chen W. The dirigent multigene family in Isatis indigotica: gene discovery and differential transcript abundance. BMC Genomics. 2014 May 20;15():388.
参考文献:10.1007/s13238-018-0549-0
摘要:Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein & Cell. 2018 May 03;9(5):416–31. doi: 10.1007/s13238-018-0549-0.
参考文献:10.1002/ijc.23614
摘要:Saarinen NM, Wärri A, Dings RP, Airio M, Smeds AI, Mäkelä S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer. 2008 Sep 01;123(5):1196–204. doi: 10.1002/ijc.23614.
📝 需求与反馈
尽可能描述清楚需求与问题信息
